Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with alopecia areata had significantly higher systemic immune-inflammation index levels compared to healthy controls, regardless of the disease's severity.

This case report describes a patient with both rheumatoid arthritis and alopecia areata who showed improvement in both conditions after treatment with baricitinib monotherapy, highlighting the importance of personalized treatment approaches in managing co-occurring autoimmune diseases.

This conference abstract outlines topics discussed at the International Conference of the Islamic Medical Association of North America and reports no new results.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This study found that ATR-FTIR spectroscopy combined with machine learning effectively differentiated alopecia areata patients from healthy controls with an AUC of 0.85, and also showed promise in predicting treatment response, particularly through alterations in the Amide I band.

This study found that Black patients with alopecia areata showed an average 20% reduction in scalp involvement after JAK inhibitor therapy, indicating positive treatment outcomes in this group.

In this retrospective study on pediatric craniospinal irradiation, researchers found that permanent radiation-induced alopecia occurred in 45.8% of patients, with higher radiation doses and treatment intensity being significant predictors, suggesting that defined dosimetric thresholds can support scalp-sparing planning.

This review highlights the potential of near-infrared light therapy to improve metabolic, antioxidant, and cognitive functions without adverse effects, and supports its use for visual and neurological conditions through molecular and cellular mechanisms, as reported in this source.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

5-ARI therapy may help prevent prostate cancer progression.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This study observed that many couples in North America undergo IUI or IVF for male infertility without specialized male factor evaluations, potentially overlooking reversible causes.

This study identified 11 previously unreported ABCA12 variants associated with varying severities of autosomal recessive congenital ichthyoses and expanded the phenotype spectrum of ichthyosis linked to these variants.

This article discusses the first international certification examination by the American Board of Hair Restoration Surgery, with no new research findings reported.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

In this study, irradiation with different ionizing particles in rabbit forebrains showed that higher LET values accelerated early expression and late deterioration of forebrain damage.

This review compiles existing research on ischemia-modified albumin (IMA) as a biomarker for myocardial ischemia, highlighting current gaps in understanding its formation and detection, with no new clinical results reported.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This journal's abstract provides no new research results, as it describes the profile and submission requirements for the Indian Journal of Applied Research (IJAR).

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.